Table 4.
Adverse events occurring during adjuvant sorafenib therapy in seven comparative studies
| Author | Sample size | Fatigue, N (%) | Hand-foot skin reaction, N (%) | Alopecia, N (%) | Rash or desquamation, N (%) | Hypertension, N (%) | Anorexia, N (%) | Hematological events, N (%) | Transaminase elevation, N (%) | Diarrhea, N (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All grades | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | All grade | Grade 3 or 4 | ||
| Bruix J | 556 | 73 (13) | 9 (1) | 389 (70) | 154 (28) | 179 (32) | – | 91 (16) | 4 (3) | 108 (19) | 24 (4) | 33 (6) | 2 (< 1) | 32 (6) | 9 (1) | 100 (18) | 56 (10) | 215 (38) | 34 (6) |
| Li J | 12 | NA | NA | 11 (92) | NA | NA | NA | NA | NA | NA | 10 (83) | NA | NA | NA | NA | NA | NA | 10 (83.3) | NA |
| Chen BF | 24 | 12 (50) | NA | 10 (42) | NA | 9 (38) | NA | 7 (29) | NA | 5 (21) | NA | 14 (58) | NA | 5 (21) | NA | NA | NA | 7 (29) | NA |
| Zhuang L | 27 | 3 (11.1) | 0 (0) | 16 (59.2) | 2 (7.4) | 3 (11.1) | 0 (0) | 5 (18.5) | 0 (0) | 1 (3.7) | 0 (0) | 3 (11.1) | 0 (0) | NA | NA | NA | NA | 5 (18.5) | 1 (3.7) |
| Wang DS | 98 | NA | NA | 3 (2.8) | NA | NA | NA | NA | NA | NA | NA | NA | NA | 21 (21.4) | NA | 20 (20.4) | NA | 7 (6.5) | NA |
| Zhang W | 32 | Grade 3 adverse effects occurred in 6 patients with sorafenib treatment (18.8%) | |||||||||||||||||
| Xia F | 34 | With only grades 1 and 2 drug-related adverse events (14 patients, 41.2% in this study) | |||||||||||||||||
NA not available